低体积运动干预对正常葡萄糖,糖尿病前期或2型糖尿病患者的血脂组的影响:随机对照试验
Oana C Marian1,2, Danqing Min1,3,4, Callum J Baker1,3,5
1Greg Brown Diabetes and Endocrine Research Laboratory, Charles Perkins Centre, The University of Sydney, New South Wales, Australia.
高强度间歇训练 (HIIT) 加上渐进性抵抗训练 (PRT) 在2型糖尿病患者中显著降低了有害的脱氧胺. 过量的l-alanine可能会导致这些脂质变化,突出显示运动对代谢健康的好处.
科学领域:
- 代谢健康 代谢健康
- 运动生理学 运动生理学
- 利皮多米克 (Lipidomics) 是一种消化剂.
背景情况:
- 2型糖尿病 (T2D) 和糖尿病前期 (PD) 与代谢失调有关.
- 血脂质谱在正常葡萄糖耐受性 (NGT),PD和T2D之间存在显著差异.
- 高强度间歇训练 (HIIT) 和渐进性抵抗训练 (PRT) 显示出改善代谢结果的潜力.
研究的目的:
- 为了比较NGT,PD和T2D的超重个体之间的血脂质样本.
- 评估12周HIIT + PRT干预措施对这些群体的循环脂质的影响.
- 为了研究氨酸和氨酸在T2D相关的脂质扰乱中的作用.
主要方法:
- 随机对照试验比较HIIT + PRT与伸展.
- 使用液体染色学-并联质谱法量化血脂质,d-和l-氨酸,d-和l-氨酸.
- 分析脂类物种,氨基酸和代谢标记物 (葡萄糖,胰岛素,HOMA-IR,HbA1c,肝脂肪) 之间的相关性.
主要成果:
- 与NGT和PD相比,T2D参与者表现出较低的斯芬戈米林和溶脂胆 (LPC),以及较高的二甲醇和脱氧胺物种.
- 在T2D组中,HIIT + PRT干预显著降低了脱氧胺.
- 在T2D中增加的l-alanine和d-alanine水平与胰岛素抵抗标志物和肝脂肪正相关;脱氧胺与l-alanine:l-serine比率相关.
结论:
- 与NGT和PD相比,T2D中的血脂质组概况在T2D中发生了重大变化.
- 过量的l-alanine可能会导致T2D中代谢不良的脱氧胺水平升高.
- 一个为期12周的HIIT + PRT计划有效地减少了T2D中的脱氧胺,独立于氨酸:氨酸比率,提供了一种新的治疗方法.
更多相关视频
12:59Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
04:54Using a Combination of Indirect Calorimetry, Infrared Thermography, and Blood Glucose Levels to Measure Brown Adipose Tissue Thermogenesis in Humans
Published on: June 2, 2023
相关概念视频
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Atherosclerosis III: Management
